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nificant difference in the incidence of sensitization to the pa-
nallergens profilin, polcalcin or both. The sensitization pat-
tern does not alter when subdividing the cohort into clini-
cally relevant and silent sensitization. We did not find 
clinically symptomatic sensitization to panallergens without 
cosensitization to a major allergen.  Conclusions: Our results 
suggest that sole sensitization to panallergens seems to have 
no clinical relevance in allergic rhinoconjunctivitis. Clinical 
complaints seem to be triggered manly by major allergens. 
Thus, component-resolved allergy diagnostics is crucial in 
the diagnosis and treatment of polysensitized patients. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Component-resolved diagnostics (CRD) is considered 
the state-of-the-art diagnostic approach to identify aller-
gen sensitization of a patient at molecular level  [1, 2] . Pol-
len extracts contain a variety of allergens, which differ in 
their allergenicity. By purifying specific immunoglobulin 
E (IgE)-binding proteins from pollen extracts or by re-
combinant protein expression in  Escherichia coli , single 
allergens can be identified and analyzed structurally and 
immunologically. Therefore, CRD based on single re-
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 Abstract 
 Background: Component-resolved diagnostics is gaining 
importance in allergy diagnostics. Allergen extracts contain 
components with different rates of prevalence and clinical 
relevance, which can be subdivided at molecular level into 
major and minor allergens. Clinical complaints are usually 
triggered by major allergens, while the role of sensitization 
to the panallergens profilin and polcalcin still remains un-
clear.  Methods: Eighty-six patients from southern Bavaria 
with sensitization to the panallergens profilin (Bet v 2/Phl p 
12) and/or polcalcin (Bet v 4/Phl p 7) were examined in regard 
to their sensitization to the 4 main botanic denominations 
Betulaceae, Oleaceae, Poaceae and Asteraceae by skin prick 
test and measurement of specific immunoglobulin E anti-
bodies to natural allergen extracts as well as major allergen 
components rPhl p 1/5, rBet v 1, rOle e 1 and nArt v 1. Sensi-
tization was rated as clinically relevant or irrelevant depend-
ing on anamnesis or intranasal allergen challenge.  Results: 
Regarding the 4 botanic denominations, there was no sig-
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combinant or natural allergen molecules enables a precise 
diagnosis of individual sensitization patterns. Symptom-
eliciting allergens can be distinguished from highly cross-
reactive allergens in polysensitized patients  [3] . CRD, 
therefore, leads to more accurate allergy diagnosis. 
 When looking at the sensitization of patients to a cer-
tain allergen source, one can distinguish between major 
and minor allergens. An allergen is considered a major 
allergen if 50% or more of the sensitized patients produce 
specific IgE to that specific allergen. In contrast, a minor 
allergen is considered as such if fewer patients produce 
specific IgE  [4] . This subdivision is irrespective of its clin-
ical relevance and has to be evaluated regionally. 
 For inhalant allergens, a wide range of recombinant 
allergens has been produced over the last years. In this 
article, we will focus on birch, ash, mugwort and timothy 
as common inhalant allergens in the western civilization. 
Major allergens are considered to be the relevant trigger 
of allergic symptoms in patients  [5] . Such major allergens 
are Bet v 1 (birch), Phl p 1 and 5 (timothy grass), Art v 1 
(mugwort plant) and Ole e 1 (olive tree), which is highly 
homologous to Fra e 1 (ash tree), respectively  [6–9] . Some 
minor allergens are widespread in pollens from different 
plants and are, therefore, called panallergens. The two 
most important groups of panallergens are profilin and 
calcium-binding proteins (polcalcins). Profilin is part of 
the eukaryotic cytoskeleton  [10] and shows great homol-
ogy throughout different plants. This leads to high cross-
reactivity of profilins. Diagnostically important profilins 
are Bet v 2 (birch) and Phl p 12 (timothy grass). Polcalcin 
participates in the signal transduction pathway in eukary-
otic cells by binding to calcium  [9] . They are widely dis-
tributed proteins in tree, grass and weed pollen  [10] . Pol-
calcins from birch and timothy grass are Bet v 4 and Phl 
p 7, respectively. Panallergens are discussed to be a cause 
of polysensitization in patients  [6] . However, the source 
of sensitization as well as its clinical relevance still re-
mains unclear. 
 In this study, we investigated the sensitization patterns 
of pollen-allergic patients sensitized to profilin, polcalcin 
or both. The study aims to reveal the clinical relevance of 
these panallergens in our patient cohort.
 Patients and Methods 
 Patient data were retrospectively selected from the allergy da-
tabase of the Department of Otorhinolaryngology, Head and Neck 
Surgery of the Ludwig Maximilian University in Munich storing 
all relevant diagnostic patient results, including data from skin 
prick tests (SPTs; ALK-Abelló, Wedel, Germany) to timothy grass, 
rye, birch, hazel, alder, ash, mugwort, pellitory, ragweed,  Derma-
tophagoides pteronyssinus ,  Dermatophagoides farinae , dog, cat, Al-
ternaria and Aspergillus. Histamine dihydrochloride solution at
1 mg/ml was used as positive control and allergen-free saline solu-
tion as negative control. SPT was considered positive with a wheal 
diameter >3 mm, which was assessed 20 min after application. The 
procedure was in line with the literature  [11] . The database in-
cludes also results from IgE measurements and allergen provoca-
tions. 
 IgE reactivity to purified natural allergen extract and allergen 
components was measured using the FEIA method (UniCAP-
FEIA, Thermo Fisher Scientific, Freiburg, Germany) with a com-
mercially available test kid (Phadia Diagnostics, Freiburg, Germa-
ny) according to the manufacturer’s instructions. Focusing on the 
4 main botanic denominations Poaceae, Betulaceae, Oleaceae and 
Asteraceae, specific IgE antibodies to the native extracts of timothy 
grass, birch, ash and mugwort were measured in case of a positive 
SPT result. The panallergens profilin (Bet v 2/Phl p 12) and polcal-
cin (Bet v 4/Phl p 7) as well as the major allergen components rPhl 
p 1/5, rBet v 1, rOle e 1 and nArt v 1 had been determined. Results 
were reported as CAP classes as well as concentrations (kU/l).
 Patients with positive in vivo  or  in vitro allergy tests do not 
necessarily suffer from an allergic disease. An accurate medical his-
tory is crucial to determine the clinical relevance of the sensitiza-
tion. Sensitizations were rated as relevant if the patient presented 
an apparent positive anamnesis for the specific allergen. In case of 
doubt, a nasal or conjunctival provocation (ALK-Abelló) indicates 
the clinical relevance of the sensitization to inhalant allergens ac-
cording to guideline specifications  [12, 13] . The intranasal provo-
cation was rated positive if the rhinomanometry decreased >40% 
at 150 Pa on the allergen-challenged side or the patient had a symp-
tom score >3. It was also rated positive with a decrease in rhino-
manometry >20% at 150 Pa on the allergen-challenged side in 
combination with a symptom score >2. Four categories of nasal 
symptoms were semiquantitatively assessed on the first visit: (1) 
obstruction, (2) rhinorrhea, (3) sneezing and (4) itching. Each 
symptom could be classified as: 0 = no impairment, 1 = mild im-
pairment, 2 = moderate impairment and 3 = severe impairment. 
Sensitization with unreliable classification because of missing an-
amnestic information or challenge data was excluded from the 
study due to its retrospective character, which renders further in 
vivo data acquisition impossible. 
 The database was scanned for consecutive patients with a prov-
en sensitization to profilin and/or polcalcin who got extensive al-
lergy diagnostics at our institution between 2009 and 2013. Of 
1,145 patients, 86 met the inclusion criteria.
 The study was approved by the local ethics committee and the 
local data protection commissioner. All patients gave informed 
consent. 
 Results 
 Sensitization Patterns of Major and Minor Allergens 
 In our cohort, patients were stratified for all 4 botan-
ic denominations by SPT. For birch (n = 80), ash (n = 
29), timothy (n = 85) and mugwort (n = 26), sensitiza-
tion to their major allergen Bet v 1, Ole e 1, Phl p 1/5 or 
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nArt v 1, respectively, was examined ( fig. 1 ). Major al-
lergen sensitization clearly predominates in patients 
sensitized to minor allergens profilin, polcalcin or both: 
78% for Bet v 1, 79% for Ole e 1, 93% for Phl p 1/5 and 
73% for nArt v 1. 
 When differentiating the sensitization to birch, ash, 
timothy and mugwort into sole sensitization to profilin 
or polcalcin or a double sensitization to both panaller-
gens, the following can be shown: Sole profilin sensitiza-
tion has the highest rate with about 70% in all groups, 
followed by the concomitant sensitization of profilin and 
polcalcin (about 20%) and the sole sensitization of polcal-
cin (about 10%;  fig. 2 ).
 Furthermore, we investigated the sensitization of the 
panallergens profilin and polcalcin within the group of 
major allergen-positive and -negative sensitization ( ta-
ble 1 ). 
 There was a similar sensitization profile to minor al-
lergens in all 4 botanic groups. Profilin clearly predomi-
nates the major allergen-positive and -negative group. 
Overall, 68% of major allergen-positive sensitization were 
found to be cosensitized to profilin. In the major allergen-
negative group of sensitization, 81% were sensitized to 
profilin. Polcalcin sensitization alone was found in 10% 
of the patients with major allergen-positive sensitization 
and in 11% with major allergen-negative sensitization. A 
double sensitization to profilin and polcalcin was found 
in a total of 22% of major allergen-positive and 8% of ma-
jor allergen-negative sensitization results.
 Clinical Relevance of Panallergens 
 Figure 3 shows the distribution of clinically irrelevant 
versus relevant sensitization in our cohort. Timothy grass 
had the highest amount of clinically relevant sensitization 
with 64%, followed by birch (46%), ash (38%) and mug-
wort (19%). 
 We further stratified the group with ( fig. 4 a) and with-
out ( fig. 4 b) clinically relevant sensitization to birch, ash, 
timothy and mugwort by their expression of IgE against 
the panallergens profilin and polcalcin.
 Table 1.  Sensitization to the panallergens profilin and polcalcin in major allergen-positive and -negative sensitization
Sensitization Major allergen positive  Major allergen negative
Profilin/polcalcin +/– –/+ +/+  +/– –/+ +/+
Birch 40 (65%) 7 (11%) 15 (24%) 16 (89%) 1 (6%) 1 (6%)
Ash 16 (70%) 3 (13%) 4 (17%) 4 (67%) 0 2 (33%)
Timothy 54 (68%) 8 (10%) 17 (22%) 5 (83%) 1 (17%) 0
Mugwort 14 (74%) 1 (5%) 4 (21%) 5 (71%) 2 (29%) 0
Total 124 (68%) 19 (10%) 40 (22%) 30 (81%) 4 (11%) 3 (8%)
100
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 Fig. 1. Sensitization to the major allergen of birch (Bet v 1), ash 
(Ole e 1), timothy (Phl p 1/5) and mugwort (Art v 1) in panaller-
gen-sensitized patients. 
 Fig. 2. Stratification by sensitization to the minor allergens profilin 
and/or polcalcin in panallergen-sensitized patients. 
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 The expression patterns in both cohorts indicate simi-
lar results regarding the single components. Profilin 
clearly predominates in clinically relevant and silent sen-
sitization in all 4 botanic denominations with an IgE ex-
pression of 62–81%, followed by the concomitant IgE ex-
pression of both panallergens in 0–24% and the sole IgE 
expression for polcalin in 6–20%. 
 To further investigate the clinical relevance of sensiti-
zation to panallergens, we conducted an analysis of symp-
tomatic and asymptomatic sensitization in regard to their 
cosensitization to major allergens ( table 2 ). In our study, 
no major allergen-negative sensitization showed to be 
symptomatic. The sensitization patterns to panallergens 
in asymptomatic sensitization showed to be similar in ma-
jor allergen-positive and -negative sensitization ( table 2 ).
 Discussion 
 CRD presents a precise method for individual allergy 
diagnostics. It is now possible to differentiate a patient’s 
specific sensitization pattern instead of dealing with natu-
ral pollen extracts containing allergens of different aller-
genicity as well as other proteins and carbohydrates in 
poorly defined concentrations  [14] leading to a lack of 
analytical specificity. Thus, a more accurate and individ-
ual identification of allergen profiles can be achieved and 
disease-eliciting allergen components might be differen-
tiated from confounders.
 By implementing molecular allergy diagnostics, a dis-
tinction between major and minor allergens was possible. 
Major allergens are considered as triggers of clinically
relevant allergy in most cases. Minor allergens are con-
sidered as markers of multiple pollen sensitization  [15] . 
Profilins and calcium-binding proteins (polcalcins) are 
widespread even in botanically unrelated sources and, 
therefore, presumed to provoke a high potential of aller-
genic cross-reactivity  [16, 17] . This cross-reactivity is dis-
cussed to be a reason for nonresponse in allergen-specif-
ic immunotherapy (AIT). The average success rate of AIT 
ranges from 80 to 85% in pollen-sensitive patients  [18] . 
As clinical symptoms in patients seem to be triggered by 
major allergen components, the success of immunothera-
pies might be largely determined by major allergens  [6] . 
Commercially available immunotherapy solutions are 
standardized for their content of major allergens only. 
Therefore, a therapeutic dosage can only be guaranteed 
for major allergens. Furthermore, especially in patients 
sensitized to multiple, taxonomically unrelated allergens, 
the clinician has to determine whether sensitization is due 
to cosensitization to different ‘genuine’ allergens or due 
100
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 Fig. 4. Sensitization to panallergens (profilin/polcalcin) in clini-
cally relevant ( a ) and silent ( b ) sensitizations to birch, ash, timothy 
grass or mugwort. 
 Fig. 3. Clinical relevance of sensitization to inhalant allergens (in 
patients sensitized to profilin and/or polcalcin). The black bars il-
lustrate the percentage of sensitizations with clinical relevance, 
and the gray bars sensitizations without clinical relevance. 
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to a corecognition of homologous panallergens  [19] . 
Thus, a sensitization to panallergens might explain at 
least part of the 15–20% who are not responding. Sole 
sensitization to panallergens can often not be attributed 
to a specific allergen source and is, therefore, not suited 
for AIT  [20] . But how clinically relevant is a sensitization 
to panallergens?
 To date, sensitization to panallergens is mainly detect-
ed by IgE reactivity in vitro. Even though SPT solutions 
with profilin and polcalcin have been developed  [21, 22] 
and used as provocation agents  [23, 24] , larger studies 
proving the clinical relevance of panallergens are lacking 
to date. 
 Sensitization and immunological cross-reactivity do 
not predict a clinically relevant allergy. Scheurer et al.  [25] 
found strong IgE reactivity to recombinant plant food 
profilins in Bet v 2-sensitized patients. Interestingly, these 
patients presented no clinical symptoms. Similar results 
were found by Wensing et al.  [26] and Ebo et al.  [27] , sug-
gesting a minor relevance of sole profilin sensitization in 
triggering relevant food allergies. As a food allergen, pro-
filin is actually described to trigger merely an oral allergy 
syndrome but it seems also able to induce severe reactions 
 [28, 29] . Several authors assume that a high rate of diges-
tion by pepsin in the gastric fluid leads to a reduced enzy-
matic stability. This, as well as low thermal stability, re-
sults in only mild allergic symptoms like the oral allergy 
syndrome  [25, 30] . Fah et al.  [31] reported a case of ana-
phylactic reaction to lychee fruit. IgE to profilin in the 
patient’s serum was the only clinical finding. The authors 
discussed that the high level of profilin might have over-
come the capacity of gastric protein digestion and there-
fore led to a high absorption of profilin, which again trig-
gered anaphylaxis.
 However, the clinical relevance of sensitization to pan-
allergens remains subject to controversy until a reliable in 
vivo provocation test is available. There is only slight evi-
dence that profilin elicits nasal and bronchial responses. 
Especially nasal responses to profilin are quite weak  [23, 
24] . In this retrospective study, we analyzed the sensitiza-
tion patterns of pollen-sensitized patients in southern Ba-
varia who were positive to panallergens. The incidence of 
sensitization to profilin and polcalcin as well as to major 
allergens was examined in panallergen-positive patients 
and their clinical relevance was assessed. Profilin was 
found to be the most common minor allergen in our pa-
tients, who showed IgE expression against profilin only 
in about 70% of the cases. These data are in agreement 
with previous studies  [6] .
 We found that sole sensitization to minor allergens 
seems to have no clinical relevance in allergic rhinocon-
junctivitis. Clinical complaints seem to be triggered by 
the major allergens. 100% of the patients with clinical 
complaints showed to be IgE positive for the specific ma-
jor allergen component. In cases of sensitization without 
clinical symptoms, a consistent distribution of sensitiza-
tion patterns to panallergens was seen irrespective of co-
sensitization to major allergens such as birch, ash, timo-
 Table 2.  Sensitization patterns to panallergens and major allergens in clinically symptomatic and asymptomatic sensitization to birch, 
ash, timothy grass or mugwort
Profilin/polcalcin Major allergen positive  Major allergen negative
+/– –/+ +/+  +/– –/+ +/+
Symptomatic sensitization
Birch 23 (62%) 5 (14%) 9 (24%) 0 0 0
Ash 8 (73%) 1 (9%) 2 (18%) 0 0 0
Timothy 34 (63%) 7 (13%) 13 (24%) 0 0 0
Mugwort 4 (80%) 1 (20%) 0 0 0 0
Total 69 (65%) 14 (13%) 24 (22%) 0 0 0
Asymptomatic sensitization
Birch 17 (68%) 2 (8%) 6 (24%) 16 (89%) 1 (6%) 1 (6%)
Ash 8 (67%) 2 (17%) 2 (17%) 4 (67%) 0 2 (33%)
Timothy 20 (80%) 1 (4%) 4 (16%) 5 (83%) 1 (17%) 0
Mugwort 10 (71%) 0 4 (29%) 5 (72%) 2 (28%) 0
Total 55 (72%) 5 (7%) 16 (21%) 30 (81%) 4 (11%) 3 (8%)
 San Nicoló/Braun/Eder/Berghaus/Gröger
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thy grass or mugwort. In case of clinically relevant sensi-
tization, the sensitization pattern to panallergens was 
found be similar to that to major allergens only. Symp-
tomatic but major allergen-negative sensitization could 
not be detected. In our study, clinical symptoms were al-
ways accompanied by sensitization to major allergens 
whereas a major allergen sensitization on its own did not 
imply clinical relevance.
 In a cross-sectional study, Scala et al.  [32]  analyzed the 
molecular profiles of over 23,000 patients in relation to 
age. A clear difference in the stratified groups was found. 
Melioli et al.  [33]  confirmed this by showing a higher rate 
of overall sensitization in adolescence than in childhood. 
Young children presented sensitization to food allergens 
while ‘genuine’ components of grass, Parietaria and birch 
were rare before the age of 3 years. Interestingly, cross-
reacting allergens were almost absent in the first years of 
childhood.
 The term ‘molecular spreading’ is used to describe the 
recent finding of an evolution of sensitization – from mo-
lecular monosensitization in early childhood to oligo- 
and polysensitization in adolescence and adulthood  [34] . 
This could indicate that sensitization to panallergens fol-
lows a sensitization to the corresponding major allergen 
over time. If sensitization to panallergens follows the sen-
sitization to the specific major allergen in a chronological 
order, major allergen sensitization should predominantly 
be seen in polysensitized patients and, therefore, allow to 
draw conclusions on the origin of the panallergen sensi-
tization  [35] . Looking at our data, rates of sensitization to 
specific major allergens in panallergen-sensitized pa-
tients correspond approximately in all 4 botanic groups. 
Remarkably, 85 of the 86 patients were sensitized to grass 
pollen, 79 (93%) of these grass pollen-sensitized subjects 
were Phl p 1/5 positive. This is in line with observations 
from others describing an interrelationship of profilin 
sensitization with grass allergy  [29, 36] . Within the other 
3 botanic groups, sensitization rates to the particular ma-
jor allergen ranged between 73 and 79%. Hence, we can-
not definitely deduce the primary source of sensitization 
to panallergens; this could be an indication of the route 
via grass pollen  [22] .
 Thus, component-resolved allergy diagnostics is im-
portant in the diagnosis of polysensitized patients. In or-
der to avoid nonresponse to AIT and a possible iatrogen-
ic sensitization  [2] , the proof of major allergen compo-
nents is crucial.
 Further investigations, especially the introduction of 
an in vivo provocation test with profilin and polcalcin as 
the gold standard in allergy diagnostics, need to be ad-
vanced to gain more insight into the role of minor aller-
gens in allergic rhinoconjunctivitis.
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